{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:59:21Z","timestamp":1790312361996,"version":"4.1.0"},"reference-count":37,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["0094904"],"award-info":[{"award-number":["0094904"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"award":["0094904"],"award-info":[{"award-number":["0094904"]}],"id":[{"id":"https:\/\/ror.org\/04txyc737","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives:\u00a0MET amplification represents the most common bypass resistance mechanism to EGFR tyrosine kinase inhibitor (TKI) treatment in EGFR-mutated non-small cell lung cancer (NSCLC). Combination therapy with the EGFR-TKI, osimertinib, and the MET-TKI, crizotinib, has demonstrated clinical efficacy in overcoming this resistance. However, assessing MET transcriptional activity during treatment remains challenging. Methods: Cell-free chromatin immunoprecipitation (cfChIP) targeting H3 lysine 36 trimethylation (H3K36me3) was employed to investigate the transcriptional activity of the EGFR and MET genes in serial liquid biopsies obtained from two patients with EGFR-mutated NSCLC. Droplet digital PCR (ddPCR) was used to quantify circulating tumor DNA (ctDNA) and cfChIP enrichment levels. Results: In PT1, H3K36me3 mEGFR and MET cfChIP enrichment increased during disease progression, with MET enrichment increasing further following the initiation of crizotinib\/osimertinib combination therapy, during which the patient experienced a partial response. In PT2, MET amplification was detected in a liquid biopsy, but MET cfChIP enrichment remained low throughout the treatment course, and the patient did not respond to crizotinib. Conclusions: This two-patient feasibility study illustrates the potential of cfChIP-ddPCR for the longitudinal assessment of EGFR and MET transcriptional activity in liquid biopsies. These observations warrant further investigation of cfChIP as an approach for monitoring transcriptional activity during osimertinib\/crizotinib treatment.<\/jats:p>","DOI":"10.3390\/cancers18193097","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:10:31Z","timestamp":1790179831000},"page":"3097","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Assessment of EGFR and MET Transcriptional Activity Using Cell-Free Chromatin Immunoprecipitation in Two Patients with EGFR-Mutated Non-Small Cell Lung Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Emma","family":"Pedersen","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3071-3437","authenticated-orcid":false,"given":"Christoffer Trier","family":"Maansson","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5788-4463","authenticated-orcid":false,"given":"Peter","family":"Meldgaard","sequence":"additional","affiliation":[{"name":"Department of Oncology, Aarhus University Hospital, 8200 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9472-8099","authenticated-orcid":false,"given":"Boe Sandahl","family":"Sorensen","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/CM9.0000000000002529","article-title":"Global burden and trends of lung cancer incidence and mortality","volume":"136","author":"Li","year":"2023","journal-title":"Chin. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment Mayo","volume":"94","author":"Duma","year":"2019","journal-title":"Clin. Proc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100076","DOI":"10.1016\/j.pharmr.2025.100076","article-title":"Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers","volume":"77","author":"Du","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cllc.2024.11.014","article-title":"Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy","volume":"26","author":"Elghawy","year":"2025","journal-title":"Clin. Lung Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: Primary results from the phase II SAVANNAH study","volume":"36","author":"Kim","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.jtho.2018.04.007","article-title":"Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition","volume":"13","author":"Deng","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lungcan.2020.06.003","article-title":"The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy","volume":"146","author":"Wang","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: Current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: Status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"12564","DOI":"10.1038\/s41598-020-69432-x","article-title":"Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR","volume":"10","author":"Alcaide","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Galant, N., Nico\u015b, M., Ku\u017anar-Kami\u0144ska, B., and Krawczyk, P. (2024). Variant Allele Frequency Analysis of Circulating Tumor DNA as a Promising Tool in Assessing the Effectiveness of Treatment in Non-Small Cell Lung Carcinoma Patients. Cancers, 16.","DOI":"10.3390\/cancers16040782"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Palac\u00edn-Aliana, I., Garc\u00eda-Romero, N., Asensi-Puig, A., Carri\u00f3n-Navarro, J., Gonz\u00e1lez-Rumayor, V., and Ayuso-Sacido, \u00c1. (2021). Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080906"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.21037\/tlcr.2016.08.06","article-title":"Pros: Can tissue biopsy be replaced by liquid biopsy?","volume":"5","author":"Hofman","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41416-021-01696-0","article-title":"Cell-free DNA analysis in current cancer clinical trials: A review","volume":"126","author":"Page","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jtho.2024.07.008","article-title":"Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3","volume":"19","author":"Gray","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/1759-7714.12793","article-title":"Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer","volume":"9","author":"Lee","year":"2018","journal-title":"Thorac. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kallergi, G., Kontopodis, E., Ntzifa, A., Jordana-Ariza, N., Karachaliou, N., Pantazaka, E., Charalambous, H.A., Psyrri, A., Tsaroucha, E., and Boukovinas, I. (2022). Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy. Cancers, 14.","DOI":"10.3390\/cancers14061574"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.21037\/tlcr-20-371","article-title":"The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment","volume":"10","author":"Ma","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6538","DOI":"10.1126\/science.aaw3616","article-title":"Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies","volume":"372","author":"Lo","year":"2021","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/1878-0261.13093","article-title":"EGFR transcription in non-small-cell lung cancer tumours can be revealed in ctDNA by cell-free chromatin immunoprecipitation (cfChIP)","volume":"15","author":"Meldgaard","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41587-020-00775-6","article-title":"ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin","volume":"39","author":"Sadeh","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.lungcan.2020.07.023","article-title":"Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients","volume":"147","author":"Meldgaard","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"103407","DOI":"10.1016\/j.dnarep.2022.103407","article-title":"The role of histone H3K36me3 writers, readers and erasers in maintaining genome stability","volume":"119","author":"Sharda","year":"2022","journal-title":"DNA Repair"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13148-021-01187-2","article-title":"H3K36 trimethylation-mediated biological functions in cancer","volume":"13","author":"Xiao","year":"2021","journal-title":"Clin. Epigenet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s00018-022-04352-9","article-title":"SETD2: From chromatin modifier to multipronged regulator of the genome and beyond","volume":"79","author":"Molenaar","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/1878-0261.13394","article-title":"Cell-free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients","volume":"17","author":"Meldgaard","year":"2023","journal-title":"Mol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1038\/oncsis.2017.17","article-title":"MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells","volume":"6","author":"Jakobsen","year":"2017","journal-title":"Oncogenesis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrclinonc.2014.41","article-title":"Li-Fraumeni syndrome: Cancer risk assessment and clinical management","volume":"11","author":"McBride","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-022-05580-6","article-title":"A DNA methylation atlas of normal human cell types","volume":"613","author":"Loyfer","year":"2023","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: A phase 1 trial","volume":"29","author":"Cho","year":"2023","journal-title":"Nat. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3097\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:15:47Z","timestamp":1790309747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/19\/3097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":37,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cancers18193097"],"URL":"https:\/\/doi.org\/10.3390\/cancers18193097","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}